BofA upgrades Apollo Global stock after a dramatic 20% decline this month: Should you consider buying?

On August 5, Bank of America upgraded Apollo Global Management to “Buy” from “Neutral” following a significant 20% drop in the company’s stock since the start of the month. BofA analysts attributed this drop to weaker-than-expected Q2 results alongside broader market pressures, including weak economic data and a lower interest rate outlook. Apollo Global Q2… Continue reading BofA upgrades Apollo Global stock after a dramatic 20% decline this month: Should you consider buying?

‘Healthy’ dollar-yen correction was overdue, former ECB chief Trichet says

The recent strengthening of the Japanese yen, resulting in a significant drop in the dollar-yen exchange rate, is seen as an overdue and healthy correction rather than a cause for panic, according to Jean-Claude Trichet, former head of the European Central Bank.  Trichet’s perspective comes amidst shifting monetary policies, geopolitical tensions, and economic data rattling… Continue reading ‘Healthy’ dollar-yen correction was overdue, former ECB chief Trichet says

OpenAI faces turmoil: Co-founder departs, Brockman steps away amidst Musk lawsuit

OpenAI is navigating a challenging period marked by leadership upheaval and renewed legal battles. Elon Musk has revived an old lawsuit against the AI company, coinciding with significant internal changes: one co-founder has left for a rival startup, and another is taking an extended leave. These developments have cast a shadow over OpenAI’s future, raising… Continue reading OpenAI faces turmoil: Co-founder departs, Brockman steps away amidst Musk lawsuit

RBC upgrades Lockheed Martin to ‘Outperform’ with $600 price target: Is it time to buy?

Lockheed Martin Corp (NYSE: LMT), the aerospace and defense major, recently received a substantial upgrade from RBC Capital, elevating the stock to “Outperform” from “Sector Perform” with a revised price target of $600, up from $500. F-35 delivery resumption a major boost This optimistic revision anticipates more than a 9% upside, driven by positive sales… Continue reading RBC upgrades Lockheed Martin to ‘Outperform’ with $600 price target: Is it time to buy?

Ford CEO Jim Farley reveals key advantage over crosstown rivals: ‘No other company has Ford Pro’

Ford Motor Co (NYSE: F) is capitalizing on its fleet business, turning what was once considered a “dirty” word in the automotive industry into a major competitive advantage. Under the leadership of CEO Jim Farley, the segment known as “Ford Pro” has generated $184.5 billion in revenue and $18.7 billion in adjusted earnings since 2021.… Continue reading Ford CEO Jim Farley reveals key advantage over crosstown rivals: ‘No other company has Ford Pro’

Stock exchange bloodbath: Wall Street’s ‘Fear Index’ VIX soars, nears pandemic market rout

The CBOE Volatility Index or VIX, which throws up market expectations for volatility over the next 30 days surged to its highest level in four years as global equities fell sharply. Investors use the VIX- dubbed as the ‘Fear Index’ to measure the level of risk, fear, or stress in the market when making investment… Continue reading Stock exchange bloodbath: Wall Street’s ‘Fear Index’ VIX soars, nears pandemic market rout

Explained: What’s the reason for global stock sell-off and who’s to blame?

Global markets experienced a significant upheaval as traders reacted to recent economic data, unwinding bets that had dominated much of the year. Japan’s Topix index suffered a dramatic fall of more than 12%, marking the most substantial sell-off since the “Black Monday” crash of 1987. This selling wave extended into US and European markets, with… Continue reading Explained: What’s the reason for global stock sell-off and who’s to blame?

RBC downgrades Moderna and cuts price target by 28%: Should you exit?

The decision by RBC Capital Markets to downgrade Moderna Inc. (NASDAQ: MRNA) from “Outperform” to “Sector Perform” has sent the stock tumbling by over 6% in pre-market trading on Monday. This downgrade reflects growing concerns about Moderna’s near-term prospects amid an increasingly challenging market for its flagship COVID-19 and RSV vaccines. Alongside the downgrade, RBC… Continue reading RBC downgrades Moderna and cuts price target by 28%: Should you exit?